Contact UsInvestorsCareersMediaScienceContact Us
HomeProductsPrescription MedicinesBosulif

This page is intended as reference information for the general public.

Bosulif® (bosutinib)

What is Bosulif and what is it used for?

Bosulif belongs to a group of medicines that target cancer cells. These medicines are called antineoplastic agents. Bosulif contains the active substance bosutinib.

It is used to treat adult patients who have a type of leukaemia called Philadelphia chromosome-positive (Ph-positive) chronic myeloid leukaemia (CML) and are newly-diagnosed or for whom previous medicines to treat CML have either not worked or are not suitable. Ph-positive CML is a cancer of the blood which makes the body produce too many of a specific type of white blood cell called granulocytes.

If you have any questions about how Bosulif works or why this medicine has been prescribed for you, ask your doctor.

Bosulif is available as tablets (100, 400 and 500 mg) and the medicine can only be obtained with a prescription.


Reference Information

The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. One of the ways they do this is by producing evidence-based guidance. See NICE guidance on Bosulif.

The Scottish Medicines Consortium is the national source of advice on the clinical and cost-effectiveness of all new medicines for NHS Scotland. Their aim is to ensure that people in Scotland have timely access to medicines that provide most benefit based on best available evidence. See SMC guidance on Bosulif.

The European Medicines Agency (EMA) is an agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Bosulif.

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Bosulif please follow these links:

Great Britain
Bosulif (bosutinib)

Northern Ireland
Bosulif (bosutinib)

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

PP-BOS-GBR-1775 / February 2023
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.